Drug Profile
Research programme: cachexia therapy - PhytoMedical Technologies
Alternative Names: BDC-03Latest Information Update: 20 Sep 2018
Price :
$50
*
At a glance
- Originator PhytoMedical Technologies
- Developer EMD Millipore; Ricerca Biosciences
- Class Obesity therapies; Phytotherapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cachexia
Most Recent Events
- 26 Aug 2011 No development reported - Preclinical for Cachexia in Canada (PO)
- 26 Aug 2011 No development reported - Preclinical for Cachexia in USA (PO)
- 12 Jul 2006 Ricerca BioSciences has entered into an agreement with PhytoMedical Technologies to develop BDC 03 for cachexia